T0	Participants 50 82	patients with advanced melanoma:
T1	Participants 640 672	patients with advanced melanoma.
T2	Participants 694 767	From January 2000 to April 2002, 132 patients were enrolled on the study.
T3	Participants 768 801	Patient and tumor characteristics
T4	Participants 843 891	Patients with cerebral metastases were included.